



SOCIETY of NEUROSCIENCES  
& REHABILITATION



WORLD PSYCHIATRIC  
ASSOCIATION



3<sup>rd</sup> Department of  
Psychiatry, School  
of Medicine AUTH

Under the auspices



School of Medicine  
Aristotle University of Thessaloniki

9<sup>th</sup> Congress on  
**Neurobiology,  
Psychopharmacology  
& Treatment Guidance**

ICNP 2024

March 8<sup>th</sup> - 10<sup>th</sup> 2024

Porto Palace Hotel, Thessaloniki, Greece



[www.psychiatry.gr](http://www.psychiatry.gr)

**Final Program**

# Leponex®

Clozapine 25 mg & 100 mg δισκία



Πριν την συνταγογράφηση συμβουλευτείτε την Περίληψη Χαρακτηριστικών του Προϊόντος που διατίθεται από την εταιρεία

#### ΛΙΑΝΙΚΕΣ ΤΙΜΕΣ:

**LEPONEX TAB 100MG/TAB ΒΤΧ50: 13,89€**

**LEPONEX TAB 25MG/TAB ΒΤΧ50: 4,12€**

Τρόπος Διάθεσης: Περιορισμένη ιατρική συνταγή από ειδικό ιατρό και παρακολούθηση κατά τη διάρκεια της αγωγής

**Για περισσότερες πληροφορίες απευθυνθείτε στην εταιρεία:**

**BGP Προϊόντα Μ.Ε.Π.Ε**

Αγ. Δημητρίου 63 • 174 56 Άλιμος • Τηλ.: 210 9891777

LEP-2023-0068-MAY23

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και  
Αναφέρετε  
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για  
ΟΛΑ τα φάρμακα  
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»



Dear colleagues,

It's a great pleasure to welcome you to the **9<sup>th</sup> Congress on Neurobiology, Psychopharmacology and Treatment Guidance** which will be held on **March 8<sup>th</sup>-10<sup>th</sup> 2024** in Thessaloniki, Greece.

This 9<sup>th</sup> Congress again aims at being valuable for the clinicians who fight daily in the front line for the treatment of real-world patients. In this frame, our goal is to provide a global and comprehensive update of the newest developments in Psychiatry and the allied sciences in a manner, which will be both focused and enriched. The rule is always to avoid content-free eloquence and authority and to face hard questions on the base of research findings.

The congress will gather again many worldwide experts to share with us their knowledge and experience once again with the support and guidance of the World Psychiatric Association and under the Auspices of the School of Medicine, Aristotle University of Thessaloniki.

During these difficult circumstances for the world, advanced education and training is the only way to the future. Novel and advanced technologies and approaches are emerging. Teaching clinical usefulness and application of new knowledge and informed treatment with psychopharmacological agents in a truly multidisciplinary approach will be the central axis of the meeting and although the congress will embrace high tech research concerning psychopathology, new treatment methods, genetics and molecular biology, it also aims on putting the emphasis on the human factor, both the therapist and the patient.

Apart from the humanistic tradition of Psychiatry and life sciences, the continuous and unconditional investment on the high level training of professionals and education of patients and their families, emerged as a significant challenge during the last few decades. Medical scientists and public health policy makers are increasingly concerned that the scientific discoveries are failing to be translated efficiently into tangible human benefit. Today, in an all the more complex and technologically advanced environment, the human factor emerges again as the most valuable one, the factor that determines the final outcome.

This 9<sup>th</sup> ICNP specifically focuses on the ultimate aim: that is to empower and eventually free patients and their families from the burden of mental disease and fighting for full remission and functional rehabilitation. It also includes the distinguished aim to spread high-level training to younger generations by including symposia organized by medical students and psychiatric residents from around the world. As hosts and organizers, we shall spare no effort in making your participation scientifically rewarding and meaningful.



**Konstantinos N. Fountoulakis**

Professor of Psychiatry, Aristotle University of Thessaloniki, Greece

Chair of the Scientific Faculty

Director, 3<sup>rd</sup> Department of Psychiatry, Aristotle University of Thessaloniki Greece  
Chair, WPA Section on Pharmacopsychiatry and Section on Evidence-Based Psychiatry



## Scientific Program

Friday, March 8<sup>th</sup> 2024

**08.00-09.30 SYMPOSIUM**

**SPECIAL ISSUES IN SCHIZOPHRENIA**

Chair: **Ioanna Gkolia**

Personality traits (Big5, Cloninger) and schizophrenia

**Ioannis Tsiptsias**

Suicidality and parasuicidal behaviors in psychosis

**Agoroula Georgiadi**

Brain gut axis, psychobiotics and their potential role in future treatments of psychosis

**Triantafyllia Kalouda**

Psychotherapy (interventions) and schizophrenia

**Georgia Erythropoulou**

**09.30-10.30 LECTURE**

Chair: **Ioannis Nimatoudis**

Are side effects necessary for treatment efficacy

**Siegfried Kasper**

**10.30-11.30 LECTURE**

Chair: **Nikitas Arnaoutoglou**

Clinical databases and research in the age of AI: lessons from an ECT and ketamine dataset

**Michael Henry**



Friday, March 8<sup>th</sup> 2024

**11.30-13.00 SYMPOSIUM**

**OVERVIEW OF TARDIVE SYNDROMES**

Chairs: **Konstantinos Fountoulakis, Nikitas Arnaoutoglou**

Epidemiology and pathophysiology

**Michaela Koumati**

Risk factors and clinical features

**Konstantinos Chovardas**

Diagnosis and differential diagnosis

**Calypso Mitkani**

Treatment and prognosis

**Athanasios Saitis**

Neurotensin / current research in Neuropeptides in stress and stress related disorders

**Grigorios Kyriatzis**

**13.00-14.30 SYMPOSIUM**

**PSYCHOTROPIC MEDICATION SIDE-EFFECTS**

Chair: **Eva-Maria Tsapakis**

Endocrinopathies

**Vasiliki Triantafyllou**

Neurological system

**Ioannis Tsambazis**

Pregnancy and the puerperium

**Alexandra Papadopoulou**

Cardiovascular system

**Marios Bantidos**

**14.30-15.00 LECTURE**

Chair: **Konstantinos Fountoulakis**

Health system's post-covid challenges

**Vasileios Kontozamanis**

*This lecture will be presented in Greek language*



Friday, March 8<sup>th</sup> 2024

**15.00-16.30 SYMPOSIUM**

**PSYCHOPHARMACOLOGY IN NEURODEVELOPMENTAL & SCHIZOPHRENIA SPECTRUM DISORDERS**

Chairs: **Eva-Maria Tsapakis, Frank Tarazi**

Psychopharmacology of autism spectrum disorders

**Frank Tarazi**

Psychopharmacology of comorbidity of ADHD and psychosis

**Kalliopi Diakaki**

Psychopharmacology of negative symptoms of schizophrenia

**Eva-Maria Tsapakis**

Psychopharmacology of neurological soft signs

**Michael Treiber**

**16.30-17.30 LECTURE**

Chair: **Eva-Maria Tsapakis**

Efficacy and tolerance of atypical antipsychotic augmentation in major depressive disorder

**Kostis Bonotis**

**17.30-18.30 LECTURE**

Chair: **Panagiotis Panagiotidis**

The tower of Babel in psychiatry - Resolving the circle of misconceptions

**Orestis Giotakos**

**18.30-19.30 LECTURE**

Chair: **Eva Maria Tsapakis**

Circadian rhythms in contemporary society

**Dimitrios Dikeos**

**19.30-20.30 LECTURE**

Chair: **Frank Tarazi**

Somatic multicomorbidty, treatment reality and mortality in mental disorders

**Konstantinos Fountoulakis**

**Saturday, March 9<sup>th</sup> 2024**

**08.00-09.30 SYMPOSIUM**

**BRAIN STIMULATION IN PSYCHIATRY**

Chairs: **George P. Chrousos, Theodoros Koutsomitros**

Non-invasive brain stimulation: a new era of mental health therapies  
**Theodoros Koutsomitros**

Augmentation of repetitive Transcranial Magnetic Stimulation (rTMS) for mood disorders  
**Andy Zamar**

Home-use transcranial Direct Current Stimulation (tDCS) in the treatment of depression  
**Sandra A. Schwarz**

**09.30-11.00 SYMPOSIUM**

**BIPOLAR SPECTRUM AND MIXED STATES: HOW TO IMPROVE THE DIAGNOSTIC APPROACH**

Chairs: **Giuseppe Tavormina, Francesco Franza**

Comorbidities, depression severity, and circadian rhythms disturbances as clinical correlates of duration of untreated illness in affective disorders  
**Patrizia Moretti**

Cognitive deficits in mood disorders: diagnostic and therapeutic trajectory  
**Francesco Franza**

Multilingual on-line GT-MSRS calculator for early diagnosis of bipolar depression and mixity states  
**Daria Smirnova**

The mixity in mixed states and in the bipolar spectrum disorders  
**Giuseppe Tavormina**

**11.00-12.00 SATELLITE SYMPOSIUM**

Chair: **Dimitris Dikeos**

Treating symptoms of psychosis. The role of cariprazine  
**Filippos Kouniakis**

Sponsored by  RECORDATI



Saturday, March 9<sup>th</sup> 2024

**12.00-12.30 SATELLITE LECTURE**

Chair: **Anastasia Konsta**

The pharmacokinetic evolution of long-acting injectable risperidone - an upgrade in schizophrenia treatment

**Petros Fotiadis**

Sponsored by  **BIAN**  
ΕΠΙΣΤΗΜΟΛΟΓΙΑ ΤΗΣ ΨΥΧΙΑΤΡΙΚΗΣ

**12.30-13.30 LECTURE**

Chair: **Ioannis Nimatoudis**

Medicinal cannabis for treating neuropsychiatric disorders

**Ilya Reznik**

**13.30-14.30 LECTURE**

Chair: **Eva-Maria Tsapakis**

Immunotherapies for Alzheimer's disease: the time is now

**Frank Tarazi**

**14.30-15.30 Break**

**15.30-17.00 SYMPOSIUM**

**NEW TARGETS FOR PSYCHOTROPIC DRUG DEVELOPMENT - FOCUS ON DEPRESSIVE DISORDERS**

Chair: **Angelos Halaris, Xenia Gonda**

The eye of the storm: the evolving role of P2X7 purinoceptors in stress, resilience, depression, anxiety, suicide, and their potential treatment

**Xenia Gonda**

Unveiling the involvement of endocannabinoids and synaptic plasticity in the antidepressant effects of ketamine and cannabidiol

**Sâmia Joca**

Mitochondrial targets for the development of novel therapeutic approaches

**Maria Skokou**

Bipolar disorders: the new thyroid disease

**Andy Zamar**



**Saturday, March 9<sup>th</sup> 2024**

**17.00-19.00 SYMPOSIUM**

**IMMUNOPSYCHIATRY AND AUTOIMMUNITY: GATEWAY TO PRECISION  
PSYCHIATRY**

Chairs: **Angelos Halaris, Janet Cunningham**

Clinical immunopsychiatry in practice - Preliminary findings and challenges  
**Janet Cunningham**

The mild encephalitis hypothesis- new findings for an extended scenario  
**Karl Bechter**

Exploring the intersection of rheumatology, infections, and psychiatry  
**Jennifer Frankovich**

PANS/PANDAS: Case presentations, lessons learned, and clinical pearls from  
treating physicians  
**Jennifer Frankovich, Angelos Halaris**

A case study of PANDAS and treatment resistant bipolar disorder  
**Angelos Halaris**

**19.00-20.00 LECTURE**

Chair: **Konstantinos Fountoulakis**

My diary; Personal millstone of my journey in psychiatry  
**Joseph Zohar**

**20.00-20.30 Awards Ceremony**



Sunday, March 10<sup>th</sup> 2024

**08.00-09.30 SYMPOSIUM**

**TELEPSYCHIATRY FOR CHILDREN AND ADOLESCENTS**

Telepsychiatry for children and adolescents: A comprehensive guide to its application and success

**Paraskevi Tatsiopoulou**

Potential pitfalls with telepsychiatry for children and adolescents

**Stella Kostikidou**

From theory to practice: Recognising and ameliorating the pitfalls

**Maria Kerasidou**

Workshop - Case scenarios

**Paschalina Kosmidou, Magdalini Matsouki, Ioanna Simigdali**

**09.30-11.00 SYMPOSIUM**

**COMMUNITY AND MENTAL HEALTH CRISIS RESOLUTION AND HOME TREATMENT INTERVENTIONS TEAMS**

Chairs: **Nikitas Arnaoutoglou, Ilias Grammatikopoulos**

The crisis resolution and home treatment older people, South Cambridgeshire and Peterborough NHS Foundation Trust - "The Doctor's and the Nurses' perspective - Part I"

**Panagiota Goulia**

The crisis resolution and home treatment older people, South Cambridgeshire and Peterborough NHS Foundation Trust - "The Doctor's and the Nurses' perspective - Part II"

**Lucy Entwistle**

The crisis resolution and home treatment older people, South Cambridgeshire and Peterborough NHS Foundation Trust - "The Doctor's and the Nurses' perspective - Part III"

**Alison Wilkinson**

Integrate mental health as part of the readiness and planning/implementation in dealing with emergency situations. The 10th Axis of the Hellenic National Action Plan for Mental Health 2021-2030

**Sotiris Koupidis**

Community based Initiatives in Northern Greece. The paradigm of Mental Health Mobile units

**Maria Sofologi**

Sunday, March 10<sup>th</sup> 2024

**11.00-12.30 SYMPOSIUM**

**INTERNATIONAL EVIDENCE-BASED TREATMENT GUIDELINES, AN UPDATE**

Chair: **Konstantinos Fountoulakis, Nikitas Arnaoutoglou**

Schizophrenia

**Konstantinos Chovardas**

Bipolar disorder

**Athanasios Saitis**

Depressive disorders

**Sofia Fylaki**

Obsessive-compulsive disorder

**Simos Karalis**

**12.30-14.00 SYMPOSIUM**

**PSYCHEDELICS IN PSYCHIATRIC TREATMENT, AN UPDATE**

Chair: **Eva Maria Tsapakis**

Pharmacology of psychedelics

**Eleni Mousiou**

MDMA and ketamine in the treatment of PTSD

**Fani Polychronidou**

Psilocybin and other classic psychedelics in depression

**Eleni Anna Kallikourdi**

Psychedelic treatments for substance use disorder and substance misuse

**Gregory Karakatsoulis**



Sunday, March 10<sup>th</sup> 2024

**14.00-15.30 SYMPOSIUM**

**OPERATIONAL STRESS ISSUES**

Chairs: **Petros Fotiadis, Panagiotis Panagiotidis**

COVID-19 crisis management, psychological support for health personnel  
**Petros Fotiadis**

Drugs and war a special relationship  
**Panagiotis Panagiotidis**

Climate change and mental health in the Hellenic Armed Forces  
**Nikolaos Moschopoulos**

War psychology - Malingering and self-inflicted wounds  
**Eleni Tsalkitzi**

Psychological warfare - fake news  
**Konstantinos Rantis**

**15.30-16.30 SYMPOSIUM**

**PSYCHOEDUCATION AND MEDICATION TREATMENT**

Chairs: **Eva Maria Tsapakis, Gregory Karakatsoulis**

Psychological perspectives and cultural attitudes towards mental illness and treatment  
**Ioanna Litsa**

Psychoeducation and dementia  
**Margarita Chanopoulou**

## General Information

### Dates and venue

March 8<sup>th</sup>-10<sup>th</sup> 2024

Porto Palace Hotel, Thessaloniki, Greece

(65, 26th Octovriou Avenue, T. +30 2310 504504, F. +30 2310 540384, [www.portopalace.gr](http://www.portopalace.gr))

### Official language

English will be the official language of the congress. No simultaneous translation will be provided.

### Congress badge

Delegates are obliged to show their congress badge at the entrance of congress hall for their attendance time to be registered.

### Certificate of attendance

All delegates will receive the certificate of attendance. Certificates will be provided after the completion of the scientific program by email.

### Presentations

Available visual equipment for all presentations will be through power point presentation. Presentations must be submitted to the technical secretariat 1 hour prior to the presentation. The use of personal computers will not be feasible.

### Exhibition

Within the congress area there will be an exhibition of pharmaceutical products.

### Registration fees

Type	Amount
Specialists	140,00€
Residents	120,00€
Other Mental Health Professionals	Free
Undergraduate Students	Free

***The above registration fees do not include 24% VAT***

### Registration fees include:

- Admission to the scientific sessions
- Certificate of attendance
- Admission to the exhibition area

### Congress Secretariat



[www.globalevents.gr](http://www.globalevents.gr)

**Thessaloniki:** 50 A Stadiou Str., 55534, Pylaia, Thessaloniki

**T** +30 2310 247743, **E** [info@globalevents.gr](mailto:info@globalevents.gr)

**Athens:** 2 Valestra str. & 168 A. Syngrou Av., 17671, Athens

**T** +30 210 3250260, **E** [athens@globalevents.gr](mailto:athens@globalevents.gr)



## Index of Speakers

### A

---

**Arnautoglou Nikitas**

Reader in Psychiatry - Teaching Faculty,  
3rd Department of Psychiatry, School of  
Medicine, Aristotle University of Thessaloniki,  
Thessaloniki, Greece

### B

---

**Bantidos Marios**

Medical Student, Aristotle University of  
Thessaloniki, Greece

**Bechter Karl**

Professor of Psychiatry and Neurology  
Ulm University, Clinic for Psychiatry and  
Psychotherapy II, Günzburg, Germany

**Bonotis Konstantinos**

Assistant Professor of Psychiatry, University  
of Thessaly, Greece

### C

---

**Chrousos George**

Emeritus Professor of Pediatrics and  
Endocrinology, National and Kapodistrian  
University, Athens,  
Director of University Research Institute  
of Maternal and Child Health & Precision  
Medicine, Greece

**Chanopoulou Margarita**

MSc Psychologist Research Associate, 3rd  
Department of Psychiatry, Aristotle University  
of Thessaloniki, AHEPA University Hospital of  
Thessaloniki, Greece

**Chovardas Konstantinos**

Psychiatry Resident, 3rd Department  
of Psychiatry, Aristotle University of  
Thessaloniki, AHEPA University Hospital of  
Thessaloniki, Greece

**Cunningham Janet**

Associate Professor, University Lecturer and  
Senior Consultant Psychiatrist, Department  
of Medical Sciences, Psychiatry, Uppsala  
University, Department of Neurosciences,  
Karolinska Institute, Stockholm, Sweden

### D

---

**Diakaki Kalliopi**

Psychiatry Resident, University Hospital of  
Heraklion, Greece

**Dikeos Dimitrios**

Professor of Psychiatry, National and  
Kapodistrian University of Athens, Greece

### E

---

**Erythropoulou Georgia**

Resident in Psychiatry, 3rd Department  
of Psychiatry, Psychiatric Hospital of  
Thessaloniki, Greece

**Entwistle Lucy**

Dementia Nurse Specialist/ team lead, CRHTT  
OP South - Cambridgeshire and Peterborough  
NHS Foundation Trust, Fulbourn Hospital,  
Cambridge, UK

**Fotiadis Petros**

Director of Military Center of Mental Health,  
424 GSNE, Thessaloniki, Greece



## F

---

**Fountoulakis Konstantinos**

Professor of Psychiatry, Director of 3rd Department of Psychiatry, Division of Neurosciences, School of Medicine, Aristotle University of Thessaloniki, Greece

**Frankovich Jennifer**

Clinical Professor, Department of Pediatrics, Division of Allergy, Immunology, Rheumatology (AIR), Stanford University, Lucile Packard Children's Hospital (LPCH), Stanford, California, USA

**Franza Francesco**

Director of Psychiatric Rehabilitation Centre "Villa dei Pini", Avellino, Italy

**Fylaki Sofia**

Psychiatry Resident, 3rd Department of Psychiatry, Aristotle University of Thessaloniki, AHEPA University Hospital of Thessaloniki, Greece

## G

---

**Georgiadi Agoroula**

Resident in Psychiatry, 3rd Department of Psychiatry, Psychiatric Hospital of Thessaloniki, Greece

**Giotakos Orestis**

Psychiatrist, Founder: Obrela Brain Hub, Athens

**Gkolia Ioanna**

Coordinating Director of Psychiatry, 1st Department of Psychiatry, Psychiatric Hospital of Thessaloniki, Greece

**Gonda Xenia**

Associate Professor, Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary

**Goulia Panagiota**

Consultant in Old Age Psychiatry, CRHTT OP South - Cambridgeshire and Peterborough NHS Foundation Trust, Fulbourn Hospital, Cambridge, UK

**Grammatikopoulos Ilias**

Consultant General Adult Psychiatrist, Dept. of Psychiatry, University Hospital Waterford, and Summerhill Community Mental Health Center, Wexford, Ireland

## H

---

**Halaris Angelos**

Emeritus Professor of Psychiatry, Chairman, Department of Psychiatry, Loyola University, Chicago Stritch School of Medicine, USA

**Henry Michael**

Director, Somatic Therapy, Medical Director, Dauten Center for Bipolar Treatment Innovation, Massachusetts General Hospital, Associate Professor of Psychiatry, Harvard Medical School, USA

## J

---

**Joca Sãmia**

Associate Professor and Co-Chair of the Neuroscience Theme Department of Biomedicine, Health Faculty, Aarhus University, Denmark

## K

---

**Kallikourdi Eleni Anna**

Medical Student, Aristotle University of Thessaloniki, Greece

**Kalouda Triantafyllia**

Resident in Psychiatry, 3rd Department of Psychiatry, Aristotle University of Thessaloniki, AHEPA University Hospital of Thessaloniki, Greece

**Karakatsoulis Gregory**

General Adult Psychiatrist, Consultant NHS, 3rd Department of Psychiatry, Aristotle University of Thessaloniki, AHEPA University Hospital of Thessaloniki, Greece

**Karalis Simos**

Psychiatry Resident, 3rd Department of Psychiatry, Aristotle University of Thessaloniki, AHEPA University Hospital of Thessaloniki, Greece

**Kasper Siegfried**

Emeritus Professor, Medical University of Vienna, Center for Brain Research, Department of Molecular Neuroscience, Vienna, Austria

**Kerasidou Maria**

Clinical Psychologist, Utrecht University, 1st Department of Psychiatry, Papageorgiou General Hospital of Thessaloniki, Greece

**Konsta Anastasia**

Associate Professor of Psychiatry, Aristotle University of Thessaloniki, Depot Antipsychotics Outpatient Unit, 1st Department of Psychiatry, Papageorgiou General Hospital, Thessaloniki, Greece

**Kontozamanis Vasileios**

Former Alternate Minister of Health, Adviser to the Prime Minister

**Kosmidou Paschalina**

Psychologist, University of Western Macedonia, Postgraduate Student MSc Clinical Mental Health Department of Medicine, Aristotle University of Thessaloniki, Greece

**Kostikidou Stella**

Psychologist, Aristotle University of Thessaloniki, MSc Clinical Psychology, Utrecht University

**Koumati Michaela**

Psychiatry Resident, Ippokrateio General Hospital of Thessaloniki, Scientific Consultant, 3rd Department of Psychiatry, Aristotle University of Thessaloniki, AHEPA University Hospital of Thessaloniki, Greece

**Kouniakos Filippos**

Psychiatrist - Psychotherapist EGO IDEAL-Institute of Mental Health, Thessaloniki, Greece

**Koupidis Sotiris**

Consultant at WHO Country Office for Greece, Occupational Doctor-Public Health, and Social Medicine Doctor

**Koutsomitros Theodoros**

Director & Founder of Greek rTMS clinic - Medical Psychotherapeutic Centre (ΙΨΚ), Thessaloniki, Greece, Consultant Psychiatrist-Psychotherapist, Clinical Director of Education - Ι.Ψ.Κ. Institute of Psychotherapy, Neuromodulation Researcher, Cognitive Neuroscience Department, Maastricht University, The Netherlands

**Kyriatzis Grigorios**

Adjunct Lecturer of Health and Environmental Biology, Democritus University of Thrace and Aristotle University of Thessaloniki, Greece

---

L

**Litsa Ioanna**

Psychologist/ psychotherapist, MSc Clinical Mental Health Aristotle University of Thessaloniki, Greece

## M

---

**Matsouki Magdalini**

Psychologist, Aristotle University of Thessaloniki,  
Postgraduate Student MSc Clinical Mental Health, School of Medicine, Aristotle University of Thessaloniki, Greece

**Mitkani Calypso**

Neurology Resident, Agios Pavlos General Hospital of Thessaloniki,  
Scientific Consultant, 3rd Department of Psychiatry, Aristotle University of Thessaloniki, AHEPA University Hospital of Thessaloniki, Greece

**Moretti Patrizia**

Department of Psychiatry, University of Perugia, Perugia, Italy

**Moschopoulos Nikolaos**

Psychiatrist, Military Center of Mental Health, 424 GSNE, Thessaloniki, Greece

**Mousiou Eleni**

Medical Student, Aristotle University of Thessaloniki, Greece

## N

---

**Nimatoudis Ioannis**

Emeritus Professor of Psychiatry, Aristotle University of Thessaloniki, Greece

## P

---

**Panagiotidis Panagiotis**

Psychiatrist, Department of Psychiatry, 424 GSNE, Thessaloniki, Greece

**Papadopoulou Alexandra**

Medical Student, Aristotle University of Thessaloniki, Greece

**Polychronidou Fani**

Medical Student, Aristotle University of Thessaloniki, Greece

## R

---

**Rantis Konstantinos**

Psychiatrist, Military Center of Mental Health, 424 GSNE, Thessaloniki, Greece

**Reznik Ilya**

Psychiatrist, MaReNa Diagnostic and Consulting Center, Bat-Yam/Tel-Aviv, Israel

## S

---

**Saitis Athanasios**

Psychiatry Resident, 3rd Department of Psychiatry, AHEPA University Hospital of Thessaloniki, Greece

**Simigdali Ioanna**

Psychologist, University of Ioannina,  
Postgraduate Student, MSc Clinical Mental Health Department of Medicine, Aristotle University of Thessaloniki, Greece

**Schwarz Sandra**

Neuromodulation Researcher, Maastricht University, The Netherlands

**Skokou Maria**

Consultant Psychiatrist, Department of Psychiatry, General University Hospital of Patras, Greece

**Smirnova Daria**

Director, International Centre for Education and Research in Neuropsychiatry (ICERN), Samara State Medical University, Samara, Russia



**Sofologi Maria**

Scientific Director - Psychologist, Mobile Unit for Adults Veroia, Adjunct Associate Professor, Department of Early Childhood Studies, University of Ioannina, Greece

T

---

**Tarazi Frank**

Associate Professor of Psychiatry and Neurology, Harvard Medical School, MGH/McLean Hospital, Boston, MA, USA

**Tatsiopolou Paraskevi**

Assistant Professor of Child and Adolescent Psychiatry, Aristotle University of Thessaloniki, 3rd Department of Psychiatry, AHEPA University Hospital of Thessaloniki, Greece

**Tavormina Giuseppe**

President, Psychiatric Studies Centre, Brescia, Italy, Senior Research Fellow, Bedfordshire Center for Mental Health Research in association with the University of Cambridge, UK

**Treiber Michael**

Psychiatry Resident, Universitätsklinik für Psychiatrie und Psychotherapie Klinische, Abteilung für Allgemeine Psychiatrie, Wien, Austria,  
Visiting Researcher, 3rd Department of Psychiatry, Aristotle University of Thessaloniki, AHEPA University Hospital of Thessaloniki, Greece

**Triantafyllou Vasiliki**

Medical Student, Aristotle University of Thessaloniki, Greece

**Tsalkitzi Eleni**

Registered Psychologist, MSc, Psychologist, Military Center of Mental Health, 424 GSNE, Thessaloniki, Greece

**Tsambazis Ioannis**

Medical Student, Aristotle University of Thessaloniki, Greece

**Tsapakis Eva-Maria**

Assistant Professor of Psychiatry, 3rd Department of Psychiatry, Aristotle University of Thessaloniki, Greece

**Tsioptsias Ioannis**

Consultant Psychiatrist, CBT and CAT Psychotherapist, 3rd Psychiatric Department of the Psychiatric Hospital of Thessaloniki, Greece

W

---

**Wilkinson Alison**

Nurse Consultant, CRHTT OP South - Cambridgeshire and Peterborough NHS, Foundation Trust, Fulbourn Hospital Cambridge, UK

Z

---

**Zamar Andy**

Gaskell Gold Medal & Prize - RCPsych  
Founder of The London Psychiatry Centre,  
Medical Director & Consultant Psychiatrist, UK

**Zohar Joseph**

Director, National Post-Trauma Center, Research Foundation, Sheba Medical Center, Israel

## Acknowledgements

The Organizing Committee wishes to thank the below-mentioned companies:



## Σημαντικές Πληροφορίες Ασφάλειας

**Αντενδείξεις:** Το Leronex αντενδείκνυται σε ασθενείς με υπερευαίσθησία στη δραστική ουσία και σε κάποιον από τα έκδοχά του, σε ασθενείς με ιστορικό τοξικής ή ιδιοσυγκρασιακής κοκκιοκυτταροπενίας/ακοκκιοκυττάρωσης (με εξαίρεση την κοκκιοκυτταροπενία /ακοκκιοκυττάρωση από προηγούμενη χημειοθεραπεία) ή σε ιστορικό ακοκκιοκυττάρωσης που προκλήθηκε από Leronex. Σε ασθενείς που δεν μπορούν να υποβληθούν σε τακτικό αιματολογικό έλεγχο. Η θεραπεία δεν πρέπει να ξεκινά ταυτόχρονα με φάρμακα που είναι γνωστό ότι έχουν σημαντικές πιθανότητες να προκαλέσουν ακοκκιοκυττάρωση ή σε ασθενείς με διαταραχή της λειτουργία του μυελού των οστών. Η ταυτόχρονη χρήση αντιψυχωσικών εναποθέσεων (derot) πρέπει να αποθαρρύνεται. Το Leronex αντενδείκνυται σε μη ελεγχόμενη επιληψία, σε αλκοολική και άλλες τοξικές ψυχώσεις, φαρμακευτική δηλητηρίαση και κωματώδεις καταστάσεις. Σε κυκλοφορική καταπληξία και /ή καταστολή του ΚΝΣ κάθε αιτιολογίας. Σε σοβαρές νεφρικές ή καρδιακές διαταραχές (π.χ. μυοκαρδίτιδα). Σε ενεργό ηπατική νόσο που συνοδεύεται με ναυτία, ανορεξία ή ίκτερος. Σε προοδευτική ηπατική νόσο, ή και ηπατική ανεπάρκεια. Σε παραλυτικό ειλεό. **Ειδικές προειδοποιήσεις και προφυλάξεις κατά τη χρήση:** • **Ακοκκιοκυττάρωση** : Το Leronex μπορεί να προκαλέσει ακοκκιοκυττάρωση. Η χρήση του περιορίζεται στους ασθενείς στους οποίους - έχουν αρχικά φυσιολογικά ευρήματα στις μετρήσεις των λευκοκυττάρων  $WBC \geq 3.500/mm^3$  ( $3,5 \times 10^9/L$ ) και  $ANC \geq 2000 mm^3$  ( $2,0 \times 10^9/L$ ) και - στους οποίους μπορεί να πραγματοποιηθούν τακτικές μετρήσεις των WBC και ANC, κάθε εβδομάδα για τις πρώτες 18 εβδομάδες και για διάστημα τουλάχιστον 4 εβδομάδων στη συνέχεια. Η παρακολούθηση πρέπει να συνεχίζεται σε όλη τη διάρκεια της θεραπείας και για 4 εβδομάδες μετά την πλήρη διακοπή του Leronex. Άμεση διακοπή του Leronex είναι υποχρεωτική αν είτε ο αριθμός των λευκών αιμοσφαιρίων WBC είναι μικρότερος από  $3000/mm^3$  ( $3,0 \times 10^9/L$ ) είτε ο απόλυτος αριθμός των ουδετερόφιλων ANC είναι μικρότερος από  $1500/mm^3$  ( $1,5 \times 10^9/L$ ) οποιαδήποτε στιγμή κατά τη διάρκεια της θεραπείας. Οι ασθενείς στους οποίους διακόπηκε εξαιτίας σημαντικής μείωσης του αριθμού των WBC είτε των ANC δεν πρέπει να εκτίθενται εκ νέου στο Leronex. Οι ασθενείς με ιστορικό πρωτοπαθών διαταραχών του μυελού των οστών μπορούν να λάβουν θεραπεία μόνο αν το όφελος υπερβαίνει τον κίνδυνο. Οι ασθενείς πρέπει να εκτιμούνται προσεκτικά από αιματολόγο πριν την έναρξη του Leronex. • **Έλεγχος του αριθμού των λευκών αιμοσφαιρίων (WBC) και του απόλυτου αριθμού των ουδετεροφίλων (ANC):** 10 ημέρες πριν την έναρξη θεραπείας πρέπει να πραγματοποιούνται μετρήσεις του αριθμού των λευκών και διαφορικών αιμοσφαιρίων ώστε να διασφαλιστεί ότι μόνο οι ασθενείς με φυσιολογικό αριθμό WBC και ANC (αριθμός  $WBC \geq 3500/mm^3$  ( $3,5 \times 10^9/L$ ) και  $ANC \geq 2000/mm^3$  ( $2,0 \times 10^9/L$ ) θα λάβουν Leronex. Μετά την έναρξη της θεραπείας πρέπει να πραγματοποιείται τακτική μέτρηση του αριθμού των λευκών αιμοσφαιρίων και του ANC και να παρακολουθείται εβδομαδιαίως για τις πρώτες 18 εβδομάδες και στη συνέχεια για διαστήματα τεσσάρων εβδομάδων τουλάχιστον. • **Ηωσινοφιλία:** Συνιστάται διακοπή, αν ο αριθμός των ηωσινοφίλων αυξηθεί πάνω από τα  $3000/mm^3$  ( $3,0 \times 10^9/L$ ). Η θεραπεία πρέπει να ξαναρχίσει μόνο όταν ο αριθμός των ηωσινοφίλων μειωθεί κάτω από  $1000/mm^3$  ( $1,0 \times 10^9/L$ ). • **Θρομβοπενία:** Συνιστάται διακοπή της θεραπείας αν ο αριθμός των αιμοπεταλίων μειωθεί κάτω από  $50.000/mm^3$  ( $50 \times 10^9/L$ ). • **Καρδιαγγειακές διαταραχές:** Μπορεί να εμφανιστεί ορθοστατική υπόταση, με ή χωρίς συγκοπή κατά τη διάρκεια της θεραπείας. Η χρήση του Leronex συνδέεται με αυξημένο κίνδυνο μυοκαρδίτιδας. Έχουν επίσης αναφερθεί περικαρδίτιδα/ περικαρδιακή συλλογή υγρού, καρδιομυοπάθεια, εμφραγμα του μυοκαρδίου, παράταση του διαστήματος QT. • Έχει παρατηρηθεί περίπου τριπλάσια αύξηση του κινδύνου για **εγκεφαλοαγγειακές ανεπιθύμητες ενέργειες**, κίνδυνος θρομβοεμβολής, επιληπτικές κρίσεις. • **Αντιχολινεργικές δράσεις:** Συνιστάται προσεκτική επίβλεψη σε ασθενείς με υπερτροφία του προστάτη και γλαύκωμα κλειστής γωνίας. Διαταραχές διαφόρων βαθμών της περισταλτικότητας του εντέρου, (δυσκοιλιότητα, εντερική απόφραξη, ενσφήνωση κοπράνων, παραλυτικός ειλεός, megacolon, έμφρακτο του εντέρου/ ισχαιμία). • Πυρετός. • Το Leronex μπορεί να προκαλέσει επιληπτικές κρίσεις, υπνηλία, ορθοστατική υπόταση, κινητική και αισθητηριακή αστάθεια, η οποία μπορεί να οδηγήσει σε πτώσεις. • Ηπατική δυσλειτουργία. • Η έναρξη της θεραπείας σε ασθενείς ηλικίας 60 ετών και άνω συνιστάται να γίνεται σε χαμηλότερη δόση. Δεν πρέπει να χορηγείται σε παιδιά και εφήβους ηλικίας κάτω των 16 ετών. • Δεν πρέπει να χρησιμοποιείται αλκοόλ ταυτόχρονα με το Leronex. Ιδιαίτερη προσοχή συνιστάται όταν χορηγείται σε ασθενείς που λαμβάνουν βενζοδιαζεπίνη ή άλλο ψυχοτρόπο παράγοντα. Η ταυτόχρονη χορήγηση ουσιών που είναι γνωστό ότι αναστέλλουν τη δραστηριότητα κάποιων ισοενζύμων του κυττοχρώματος P450 μπορεί να αυξήσει τα επίπεδα της κλοζαπίνης και η δόση της κλοζαπίνης πιθανά πρέπει να ελαττωθεί. • Πρέπει να δίδεται προσοχή όταν συνταγογραφείται σε εγκύους γυναίκες. Οι μητέρες που λαμβάνουν Leronex δεν πρέπει να θηλάζουν. • Περιέχει μονούδρική λακτόζη.

1. Περίληψη Χαρακτηριστικών Προϊόντος Leronex, 04/2023



# LYRICA®

## PREGABALIN



### Λιανικές Τιμές

Σκληρά καψάκια		Φιάλη	
25 mg/cap x 56 caps	3,68€	473 ml	52,51€
50 mg/cap x 56 caps	14,18€		
75 mg/cap x 56 caps	10,74€		
100 mg/cap x 21 caps	7,75€		
150 mg/cap x 56 caps	15,51€		
300 mg/cap x 56 caps	29,31€		

Για περισσότερες πληροφορίες απευθυνθείτε στην εταιρεία:



UPJOHN HELLAS Ε.Π.Ε. Αγίου Δημητρίου 63 • 174 56, Άλιμος  
 ΑΡ. Γ.Ε.ΜΗ 148421801000, Τηλ: (+30) 210 9891777  
 GPA Pharmaceuticals Ltd Βασιλώς Παύλου Α', 11, 1096 Λευκωσία, Κύπρος,  
 Τηλ.: +357 22863100.

Πριν την συνταγογράφηση συμβουλευτείτε την  
 Περίληψη Χαρακτηριστικών του Προϊόντος που  
 διατίθεται από την εταιρεία

Τρόπος Διάθεσης: Φαρμακευτικό προϊόν για το  
 οποίο απαιτείται ιατρική συνταγή

**Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και  
 Αναφέρετε  
 ΟΛΕΣ τις ανεπιθύμητες ενέργειες για  
 ΟΛΑ τα φάρμακα  
 Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»**

